Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.

Rodrigue A, Margaillan G, Torres Gomes T, Coulombe Y, Montalban G, da Costa E Silva Carvalho S, Milano L, Ducy M, De-Gregoriis G, Dellaire G, Araújo da Silva W Jr, Monteiro AN, Carvalho MA, Simard J, Masson JY.

Nucleic Acids Res. 2019 Nov 18;47(20):10662-10677. doi: 10.1093/nar/gkz780.

PMID:
31586400
2.

The Tumor Suppressor PALB2: Inside Out.

Ducy M, Sesma-Sanz L, Guitton-Sert L, Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron MC, Côté J, Simard J, Masson JY.

Trends Biochem Sci. 2019 Mar;44(3):226-240. doi: 10.1016/j.tibs.2018.10.008. Epub 2019 Jan 10. Review.

PMID:
30638972
3.

Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.

Margaillan G, Lévesque É, Guillemette C.

J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):85-93. doi: 10.1016/j.jsbmb.2015.09.021. Epub 2015 Sep 15.

PMID:
26385605
4.

Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.

Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, Guillemette C.

Drug Metab Dispos. 2015 Sep;43(9):1331-5. doi: 10.1124/dmd.115.065391. Epub 2015 Jun 15.

5.

Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing.

Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E, Droit A, Guillemette C.

Pharmacogenomics J. 2016 Feb;16(1):60-70. doi: 10.1038/tpj.2015.20. Epub 2015 Apr 14.

6.

Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues.

Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C.

Drug Metab Dispos. 2015 Apr;43(4):611-9. doi: 10.1124/dmd.114.062877. Epub 2015 Feb 3.

7.

Modulation of the UGT2B7 enzyme activity by C-terminally truncated proteins derived from alternative splicing.

Ménard V, Collin P, Margaillan G, Guillemette C.

Drug Metab Dispos. 2013 Dec;41(12):2197-205. doi: 10.1124/dmd.113.053876. Epub 2013 Oct 2.

PMID:
24088326
8.

The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.

Malenfant S, Margaillan G, Loehr JE, Bonnet S, Provencher S.

Expert Rev Respir Med. 2013 Feb;7(1):43-55. doi: 10.1586/ers.12.83. Review.

PMID:
23362814

Supplemental Content

Loading ...
Support Center